Baseline HbA1c, BMI, and Diabetes Duration Predict Who Responds Best to Liraglutide

Baseline HbA1c, baseline BMI, and duration of type 2 diabetes were significant predictors of liraglutide response (p<0.05). The combined ROC area under the curve was 0.851 (95% CI: 0.793-0.910), indicating good predictive accuracy.

Retrospective cohort study of 417 patients with T2DM and metabolic syndrome receiving liraglutide for 6+ months. Of these, 206 completed follow-up. Responders were defined as achieving HbA1c reduction ≥1.0% AND weight loss ≥3%. Binary logistic regression identified predictive factors, validated by ROC analysis.

Not everyone responds equally to GLP-1 drugs, and they're expensive. Identifying simple, readily available clinical markers that predict who will benefit most helps clinicians make more informed prescribing decisions and set realistic expectations for patients starting liraglutide.

As GLP-1 receptor agonists become increasingly prescribed for both diabetes and obesity, understanding which patients will benefit most becomes critical for healthcare resource allocation. This study contributes to the growing field of precision medicine in diabetes, where treatment selection is tailored to individual patient characteristics rather than one-size-fits-all protocols.

Retrospective design with nearly half of enrolled patients lost to follow-up (211 of 417). Single-center study from China may not generalize to other populations. The response definition (HbA1c ≥1% + weight ≥3%) is somewhat arbitrary. Didn't account for diet, exercise, or medication adherence, which significantly affect outcomes.